Glenmark’s PMS study allays concerns on use of Favipiravir for Covid-19 treatment
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
The study was conducted in patients with mild to moderate COVID-19
Subscribe To Our Newsletter & Stay Updated